Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Shareholder Meeting (November 2021)
15 slides from Rhythm Biosciences's shareholder meeting presentation, Nov 24, 2021
Slide 1: AGM Presentation
AGM Presentation 24 November 2021 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction Rhythm’s initial product, ColoSTAT® is a simple, low-cost blood test for the early detection of colorectal cancer for global mass-market screening. IP protection secured in all major international jurisdictions. 3
Slide 4: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code RHY $7,000,000 $2.50 $6,000,000 Share Price (at 23 November 2021) $1.74 $2.00 $5,000,000 Shares on Issue 208.8 M $1.50 $4,000,000 Unlisted Options 16.8 M $3,000,000 $1.00 Market Capitalisation $363 M $2,000,000 $0.50 $1,000,000 Cash in ba
Slide 5: Colorectal Cancer
Colorectal Cancer COLORECTAL CANCER RISK FACTORS Globally, Colorectal Cancer is currently the 3rd largest cancer by volume with 1.9 million new cases diagnosed annually and 2nd largest cause of cancer related deaths. GLOBAL BURDEN 1.93 million new cases ~940,000 deaths DIAGNOSIS BY STAGE CURRENT TES
Slide 6: Key Achievements FY’21
Key Achievements FY’21 Technology Performance • Technical validation of four final adjunct biomarkers • Study 6 completed - Sensitivity of 84% at supporting the key lead biomarker for ColoSTAT®; Specificity of 95%; and • Stable and reproduceable; and • Confirms very high accuracy - 33% better than •
Slide 7: ColoSTAT® - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? ColoSTAT® detects colorectal How it cancer – not just blood in works faeces. ColoSTAT® Technology Sample Result Low cost assay format which is designed to integrate seamlessly with existing pathology lab infrastructure ColoSTAT® Test-Kit Algorithm Blood coll
Slide 8: ColoSTAT® Performance
ColoSTAT® Performance “83% of unscreened participants prefer a blood test over a faecal test”1 ColoSTAT Sensitivity Performance Comparison • Highly accurate 85% ColoSTAT is 33% more accurate at detecting colorectal cancer than the 84% current market standard Faecal Immunochemical Test (FIT).2 80% 75
Slide 9: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market US$38 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States 63% 94 million $12Bn
Slide 10: Australia – Growth of CRC in younger age groups
Australia – Growth of CRC in younger age groups 25 – 29 years old 30 – 34 years old 35 – 39 years old 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 0 0 0 1 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 7 7 8 8 8 9 9 9 10 10 10 11 11 11 12 12 12 13 13
Slide 11: Unique Opportunity To Add Significant Value
Unique Opportunity To Add Significant Value Seamless alignment across the entire value chain providing broader benefits for the health system Blood test is the Patients preferred testing method. Increased participation in screening. Cheaper testing leads to More lives saved. Reduced Government highe
Slide 12: On Track For Future Milestones
On Track For Future Milestones Clinical Trial (Study 7) Regulatory • Commenced remaining clinical trial tasks; • CE Mark submission and approval expected in • Reduced variability in cost and time with patient late 2021; and recruitment completed; and • Progression of TGA (Australia) regulatory • On
Slide 13: The Team In Action!
The Team In Action! note: photos represent part of the entire lab team. Some team members were not present on the day these photos were taken. 13
Slide 14: Summary
Summary Disruptive and transformative technology Significantly cheaper and easier to administer Globally addressable market Performance better than market standard Manufacturing & Patents secured Initial revenues targeted for 2022 14
Slide 15: Glenn Gilbert, CEO, Rhythm Biosciences
Glenn Gilbert CEO, Rhythm Biosciences glenn.gilbert@rhythmbio.com +61 3 8256 2880 www.rhythmbio.com 15
Rhythm Biosciences — Shareholder Meeting (November 2021) on 6ix